Latif Armiyaw1, Camila Sarcone1, Andin Fosam1, Ranganath Muniyappa1. 1. Clinical Endocrine Section, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Abstract
BACKGROUND: Primary insulin hypersecretion predicts type 2 diabetes (T2DM) independent of insulin resistance. Enhanced β-cell glucose responsivity contributes to insulin hypersecretion. African Americans (AAs) are at a higher risk for T2DM than non-Hispanic Whites (NHWs). Whether AAs manifest primary insulin hypersecretion is an important topic that has not been examined systematically. OBJECTIVE: To examine if nondiabetic AA adults have a higher β-cell glucose responsivity compared with NHWs. METHODS: Healthy nondiabetic AA (n = 18) and NHW (n=18) subjects were prospectively recruited. Indices of β-cell function, acute C-peptide secretion (X0); basal (Φ B), first-phase (Φ 1), second-phase (Φ 2), and total β-cell responsivity to glucose (Φ TOT), were derived from modeling of insulin, C-peptide, and glucose concentrations during an intravenous glucose tolerance test. Insulin sensitivity was assessed by the hyperinsulinemic-euglycemic glucose clamp technique. RESULTS: Glucose disposal rate (GDR) during clamp was similar in AAs and NHWs (GDR: [AA] 12.6 ± 3.2 vs [NHW] 12.6 ± 4.2 mg/kg fat free mass +17.7/min, P = .49). Basal insulin secretion rates were similar between the groups. AA had significantly higher X0 (4423 ± 593 vs 1807 ± 176 pmol/L, P = .007), Φ 1 [377.5 ± 59.0 vs 194.5 ± 26.6 (109) P = 0.03], and Φ TOT [76.7 ± 18.3 vs 29.6 ± 4.7 (109/min), P = 0.03], with no significant ethnic differences in Φ B and Φ 2. CONCLUSIONS: Independent of insulin sensitivity, AAs showed significantly higher first-phase and total β-cell responsivity than NHWs. We propose that this difference reflects increased β-cell responsivity specifically to first-phase readily releasable insulin secretion. Future studies are warranted to identify mechanisms leading to primary β-cell hypersensitivity in AAs. Published by Oxford University Press on behalf of the Endocrine Society 2020.
BACKGROUND:Primary insulin hypersecretion predicts type 2 diabetes (T2DM) independent of insulin resistance. Enhanced β-cell glucose responsivity contributes to insulin hypersecretion. African Americans (AAs) are at a higher risk for T2DM than non-Hispanic Whites (NHWs). Whether AAs manifest primary insulin hypersecretion is an important topic that has not been examined systematically. OBJECTIVE: To examine if nondiabetic AA adults have a higher β-cell glucose responsivity compared with NHWs. METHODS: Healthy nondiabetic AA (n = 18) and NHW (n=18) subjects were prospectively recruited. Indices of β-cell function, acute C-peptide secretion (X0); basal (Φ B), first-phase (Φ 1), second-phase (Φ 2), and total β-cell responsivity to glucose (Φ TOT), were derived from modeling of insulin, C-peptide, and glucose concentrations during an intravenous glucose tolerance test. Insulin sensitivity was assessed by the hyperinsulinemic-euglycemic glucose clamp technique. RESULTS:Glucose disposal rate (GDR) during clamp was similar in AAs and NHWs (GDR: [AA] 12.6 ± 3.2 vs [NHW] 12.6 ± 4.2 mg/kg fat free mass +17.7/min, P = .49). Basal insulin secretion rates were similar between the groups. AA had significantly higher X0 (4423 ± 593 vs 1807 ± 176 pmol/L, P = .007), Φ 1 [377.5 ± 59.0 vs 194.5 ± 26.6 (109) P = 0.03], and Φ TOT [76.7 ± 18.3 vs 29.6 ± 4.7 (109/min), P = 0.03], with no significant ethnic differences in Φ B and Φ 2. CONCLUSIONS: Independent of insulin sensitivity, AAs showed significantly higher first-phase and total β-cell responsivity than NHWs. We propose that this difference reflects increased β-cell responsivity specifically to first-phase readily releasable insulin secretion. Future studies are warranted to identify mechanisms leading to primary β-cell hypersensitivity in AAs. Published by Oxford University Press on behalf of the Endocrine Society 2020.
Entities:
Keywords:
African Americans; insulin sensitivity; β-cell function
Authors: Ranganath Muniyappa; Rajaram J Karne; Gail Hall; Sonja K Crandon; Joel A Bronstein; Maria R Ver; Glen L Hortin; Michael J Quon Journal: Diabetes Date: 2006-11 Impact factor: 9.461
Authors: J D Brunzell; R P Robertson; R L Lerner; W R Hazzard; J W Ensinck; E L Bierman; D Porte Journal: J Clin Endocrinol Metab Date: 1976-02 Impact factor: 5.958
Authors: S M Haffner; G Howard; E Mayer; R N Bergman; P J Savage; M Rewers; L Mykkänen; A J Karter; R Hamman; M F Saad Journal: Diabetes Date: 1997-01 Impact factor: 9.461
Authors: Charmaine S Tam; Wenting Xie; William D Johnson; William T Cefalu; Leanne M Redman; Eric Ravussin Journal: Diabetes Care Date: 2012-04-17 Impact factor: 19.112
Authors: Janet W Rich-Edwards; Ursula B Kaiser; Grace L Chen; JoAnn E Manson; Jill M Goldstein Journal: Endocr Rev Date: 2018-08-01 Impact factor: 19.871
Authors: Meera Ladwa; Oluwatoyosi Bello; Olah Hakim; Fariba Shojaee-Moradie; Maria Linda Boselli; Geoff Charles-Edwards; Janet Peacock; A Margot Umpleby; Stephanie A Amiel; Riccardo C Bonadonna; Louise M Goff Journal: BMJ Open Diabetes Res Care Date: 2021-03
Authors: Katsiaryna Prystupa; Rebecka Renklint; Youssef Chninou; Julia Otten; Louise Fritsche; Sebastian Hoerber; Andreas Peter; Andreas L Birkenfeld; Andreas Fritsche; Martin Heni; Robert Wagner Journal: BMJ Open Diabetes Res Care Date: 2022-09